IDYA (Ideaya Biosciences Inc) has impressive results

While Ideaya Biosciences Inc has overperformed by 0.45%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IDYA rose by 141.97%, with highs and lows ranging from $42.80 to $13.29, whereas the simple moving average jumped by 62.37% in the last 200 days.

On August 08, 2023, SVB Securities started tracking Ideaya Biosciences Inc (NASDAQ: IDYA) recommending Outperform.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Analysis of Ideaya Biosciences Inc (IDYA)

Further, the quarter-over-quarter decrease in sales is -72.94%, showing a negative trend in the upcoming months.

To gain a thorough understanding of Ideaya Biosciences Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -23.54% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 19.37, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

It is also very valuable to look at average volume as an indicator of volatility for a stock, and IDYA is recording an average volume of 1.10M. On a monthly basis, the volatility of the stock is set at 3.93%, whereas on a weekly basis, it is put at 3.89%, with a gain of 5.28% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.40, showing decline from the present price of $42.66, which can serve as yet another indication of whether IDYA is worth investing in or should be passed over.

How Do You Analyze Ideaya Biosciences Inc Shares?

The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 13.83%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 73.88% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

Are institutional investors increasing their holdings in IDYA shares?

The recent increase in stakes in IDYA appears to be a result of several institutional investors and hedge funds increasing their positions. BVF Partners LP’s position in IDYA has decreased by -7.04% in the first quarter. The company now owns 5,283,489 shares of the stock, with a value of $187.99 million, following the sale of -400,000 additional shares during the last quarter. BlackRock Fund Advisors made another increased to its shares in IDYA during the first quarter, upping its stake by 4.88%. During the last quarter, the company dropped down 186,167 additional shares for a total stake of worth $142.42 million, bringing number of shares owned by the company to 4,002,848.

During the first quarter, Federated Global Investment Manag subtracted a -5,900 position in IDYA. T. Rowe Price Associates, Inc. purchased an additional 0.52 million shares in the last quarter, increasing its holdings by 21.21%, now holding 3.0 million shares worth $106.69 million. At the end of the first quarter, The Vanguard Group, Inc. increased its IDYA holdings by 5.09% and now holds 2.84 million IDYA shares valued at $101.2 million with the added 0.14 million shares during the period. IDYA shares are owned by institutional investors to the tune of 73.88% at present.

Related Posts